Mohamed Asif Chinnaratha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohamed Asif Chinnaratha has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Richard John Woodman
College of Medicine & Public Health, Flinders University, Adelaide, SA 5042, Australia
8 shared publications - Alan J. Wigg
Flinders University of South Australia A
4 shared publications - Edmund Tse
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, CALHN, Port Rd, Adelaide, SA 5000, Australia
4 shared publications Alan J Wigg
Hepatology and Liver Transplantation Medicine Unit, Flinders Medical Centre, Bedford Park, South Australia, Australia
3 shared publications- Alan J. Wigg
Hepatology and Liver Transplant Medicine Unit, Flinders Medical Centre, Adelaide, South Australia, Australia
3 shared publications Derrick Tee
Department of Gastroenterology/ Hepatology, Lyell McEwin Hospital, Haydown Road, Elizabeth Vale, South Australia 5112, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia
3 shared publications
Latest Publications
- 16 September 2024
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
The Efficacy of Microbiome-Targeted Therapy in Modulating Gut Health in Alcohol-Induced Liver Injury: A Systematic Review and Meta-Analysis
INPLASY202490059 The Efficacy of Microbiome-Targeted Therapy in Modulating Gut Health in Alcohol-Induced Liver Injury: A Systematic Review and Meta-Analysis Keywords: gut microbiome; microbiome tar…
- 16 September 2024
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
The Efficacy of Microbiome-Targeted Therapy in Modulating Gut Health in Alcohol-Induced Liver Injury: A Systematic Review and Meta-Analysis
INPLASY202490059 The Efficacy of Microbiome-Targeted Therapy in Modulating Gut Health in Alcohol-Induced Liver Injury: A Systematic Review and Meta-Analysis Keywords: gut microbiome; microbiome tar…
- 9 January 2022
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (7) , 1131-1136
Hepatocellular carcinoma (HCC) is changing its face: analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia
Background: The epidemiology of chronic liver disease is changing with the introduction of potent antiviral therapies for chronic hepatitis C virus (HCV) and the increasing prevalence of non‐alcoholic steatohepatitis (NASH).Aim: To establish the impact of this change on the rates and clinical patterns of hepatocellular carcinoma (HCC) in South Australia (SA).Methods: Newly diagnosed HCC patients from January 2014 until December 2019 from four tertiary centres in SA were included. The overall age‐standardised incidence rates (ASIR) of HCC were calculated using 2016 SA population as the standard. To assess the trends, Join‐Point regression models were used to calculate the average annual percentage change (AAPC). Forecasting of overall and aetiology‐specific HCC from 2020 to 2024 was performed using linear regression.Results: There were 626 new cases of HCC in SA (males 80%; median age 64 years) during the study period. There was a significant increase in NASH‐related HCC (AAPC: +7.0%; P < 0.05) from 2014 to 2019. However, there were no significant differences in the ASIR for overall HCC (AAPC: −4.1%), HCV‐related HCC (AAPC: −8.0%) and stage of HCC diagnosis (AAPC: +3.0%; P > 0.05). Forecasting analysis projected the decline and increase in the incidence of HCV and NASH‐related HCC, respectively, over the next few years.Conclusion: Overall ASIR of HCC has plateaued in SA. However, NASH‐related HCC has increased significantly and is expected to continue to increase in the near future. Further research and intervention is required to reduce NASH‐related HCC, a major contributor to the current and future burden of HCC.
- 9 January 2022
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (7) , 1131-1136
Hepatocellular carcinoma (HCC) is changing its face: analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia
Background: The epidemiology of chronic liver disease is changing with the introduction of potent antiviral therapies for chronic hepatitis C virus (HCV) and the increasing prevalence of non‐alcoholic steatohepatitis (NASH).Aim: To establish the impact of this change on the rates and clinical patterns of hepatocellular carcinoma (HCC) in South Australia (SA).Methods: Newly diagnosed HCC patients from January 2014 until December 2019 from four tertiary centres in SA were included. The overall age‐standardised incidence rates (ASIR) of HCC were calculated using 2016 SA population as the standard. To assess the trends, Join‐Point regression models were used to calculate the average annual percentage change (AAPC). Forecasting of overall and aetiology‐specific HCC from 2020 to 2024 was performed using linear regression.Results: There were 626 new cases of HCC in SA (males 80%; median age 64 years) during the study period. There was a significant increase in NASH‐related HCC (AAPC: +7.0%; P < 0.05) from 2014 to 2019. However, there were no significant differences in the ASIR for overall HCC (AAPC: −4.1%), HCV‐related HCC (AAPC: −8.0%) and stage of HCC diagnosis (AAPC: +3.0%; P > 0.05). Forecasting analysis projected the decline and increase in the incidence of HCV and NASH‐related HCC, respectively, over the next few years.Conclusion: Overall ASIR of HCC has plateaued in SA. However, NASH‐related HCC has increased significantly and is expected to continue to increase in the near future. Further research and intervention is required to reduce NASH‐related HCC, a major contributor to the current and future burden of HCC.
- 1 November 2021
- Published by Elsevier in Digestive and Liver Disease
- Vol. 53 (11) , 1396-1403
Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis
- 1 November 2021
- Published by Elsevier in Digestive and Liver Disease
- Vol. 53 (11) , 1396-1403
Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis
- 31 December 2019
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 32 (10) , 1381-1389
Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience
Aim: The objective was to study the long-term (lifetime) cost effectiveness of four different hepatitis C virus (HCV) treatment models of care (MOC) with directly acting antiviral drugs. Methods: A cohort Markov model-based probabilistic cost-effectiveness analysis (CEA) was undertaken extrapolating to up to 30 years from cost and outcome data collected from a primary study involving a real-life Australian cohort. In this study, noncirrhotic patients treated for HCV from 1 March 2016 to 28 February 2017 at four major public hospitals and liaising sites in South Australia were studied retrospectively. The MOC were classified depending on the person providing patient workup, treatment and monitoring into MOC1 (specialist), MOC2 (mixed specialist and hepatitis nurse), MOC3 (hepatitis nurse) and MOC4 (general practitioner, GP). Incremental costs were estimated from the Medicare perspective. Incremental outcomes were estimated based on the quality-adjusted life years (QALY) gained by achieving a sustained virological response. A cost-effectiveness threshold of Australian dollar 50 000 per QALY gained, the implicit criterion used for assessing the cost-effectiveness of new pharmaceuticals and medical services in Australia was assumed. Net monetary benefit (NMB) estimates based on this threshold were calculated. Results: A total of 1373 patients, 64% males, mean age 50 (SD ±11) years, were studied. In the CEA, MOC4 and MOC2 clearly dominated MOC1 over 30 years with lower costs and higher QALYs. Similarly, NMB was the highest in MOC4, followed by MOC2. Conclusion: Decentralized care using GP and mixed consultant nurse models were cost-effective ways of promoting HCV treatment uptake in the setting of unrestricted access to new antivirals.
- 31 December 2019
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 32 (10) , 1381-1389
Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience
Aim: The objective was to study the long-term (lifetime) cost effectiveness of four different hepatitis C virus (HCV) treatment models of care (MOC) with directly acting antiviral drugs. Methods: A cohort Markov model-based probabilistic cost-effectiveness analysis (CEA) was undertaken extrapolating to up to 30 years from cost and outcome data collected from a primary study involving a real-life Australian cohort. In this study, noncirrhotic patients treated for HCV from 1 March 2016 to 28 February 2017 at four major public hospitals and liaising sites in South Australia were studied retrospectively. The MOC were classified depending on the person providing patient workup, treatment and monitoring into MOC1 (specialist), MOC2 (mixed specialist and hepatitis nurse), MOC3 (hepatitis nurse) and MOC4 (general practitioner, GP). Incremental costs were estimated from the Medicare perspective. Incremental outcomes were estimated based on the quality-adjusted life years (QALY) gained by achieving a sustained virological response. A cost-effectiveness threshold of Australian dollar 50 000 per QALY gained, the implicit criterion used for assessing the cost-effectiveness of new pharmaceuticals and medical services in Australia was assumed. Net monetary benefit (NMB) estimates based on this threshold were calculated. Results: A total of 1373 patients, 64% males, mean age 50 (SD ±11) years, were studied. In the CEA, MOC4 and MOC2 clearly dominated MOC1 over 30 years with lower costs and higher QALYs. Similarly, NMB was the highest in MOC4, followed by MOC2. Conclusion: Decentralized care using GP and mixed consultant nurse models were cost-effective ways of promoting HCV treatment uptake in the setting of unrestricted access to new antivirals.
- 15 April 2019
- Published by Wiley in Anz Journal of Surgery
- Vol. 89 (9) , 1138-1143
Stereotactic body radiation therapy for early hepatocellular carcinoma: a retrospective analysis of the South Australian experience
Background Stereotactic body radiation therapy (SBRT) is an emerging treatment option for liver tumours unsuitable for established curative treatment such as ablation or surgery. The aim of the study is to evaluate the efficacy and safety of SBRT in the treatment of small hepatocellular carcinoma (HCC) in South Australia. Methods From 2014 to 2018, 13 HCC patients were treated with SBRT. Eligibility criteria for SBRT included: unsuitable for standard curative therapies (resection or percutaneous ablation), lack of complete response to prior transarterial chemoembolization, Child–Pugh classification ≤B7, tumours ≤5 cm and minimum of up to 6 months follow‐up post‐SBRT. The prescribed radiation dose was determined by liver function with doses ranging from 40 to 45 Gy in three or five fractions. Records for all patients were reviewed, and treatment response was scored according to the modified response evaluation criteria in solid tumours. Toxicity was graded according to the Common Terminology Criteria for Adverse Events version 4.0. Results The median follow‐up time was 22.7 months, and the median tumour size was 40 mm. The 1 year local control was 92.3%, recurrence‐free survival was 67.7% and overall survival was 86.4% at end of study. Three patients underwent liver transplant. No grade ≥3 non‐haematological toxicities were observed. One patient experienced acute grade ≥3 haematological toxicity. Conclusion SBRT is a safe, effective and non‐invasive alternative treatment option for patients with small HCCs, unsuitable for standard, evidence‐based therapies and lacking complete response to transarterial chemoembolization. Randomized controlled trials are required to further investigate the role of SBRT in HCC.
- 15 April 2019
- Published by Wiley in Anz Journal of Surgery
- Vol. 89 (9) , 1138-1143
Stereotactic body radiation therapy for early hepatocellular carcinoma: a retrospective analysis of the South Australian experience
Background Stereotactic body radiation therapy (SBRT) is an emerging treatment option for liver tumours unsuitable for established curative treatment such as ablation or surgery. The aim of the study is to evaluate the efficacy and safety of SBRT in the treatment of small hepatocellular carcinoma (HCC) in South Australia. Methods From 2014 to 2018, 13 HCC patients were treated with SBRT. Eligibility criteria for SBRT included: unsuitable for standard curative therapies (resection or percutaneous ablation), lack of complete response to prior transarterial chemoembolization, Child–Pugh classification ≤B7, tumours ≤5 cm and minimum of up to 6 months follow‐up post‐SBRT. The prescribed radiation dose was determined by liver function with doses ranging from 40 to 45 Gy in three or five fractions. Records for all patients were reviewed, and treatment response was scored according to the modified response evaluation criteria in solid tumours. Toxicity was graded according to the Common Terminology Criteria for Adverse Events version 4.0. Results The median follow‐up time was 22.7 months, and the median tumour size was 40 mm. The 1 year local control was 92.3%, recurrence‐free survival was 67.7% and overall survival was 86.4% at end of study. Three patients underwent liver transplant. No grade ≥3 non‐haematological toxicities were observed. One patient experienced acute grade ≥3 haematological toxicity. Conclusion SBRT is a safe, effective and non‐invasive alternative treatment option for patients with small HCCs, unsuitable for standard, evidence‐based therapies and lacking complete response to transarterial chemoembolization. Randomized controlled trials are required to further investigate the role of SBRT in HCC.
- 18 March 2019
- Published by Wiley in Emergency Medicine Australasia
- Vol. 31 (3) , 479-482
Caustic ingestion: Has the role of the gastroenterologist burnt out?
Caustic ingestion is a frequent presentation to EDs and encompasses a wide range of injury to the gastrointestinal tract. Endoscopy has long been considered the gold standard of investigation, even in patients with low likelihood of severe injury, and informs the decision for emergency surgery. However, recent evidence suggests that computed tomography (CT) scan can accurately diagnose digestive tract necrosis and, more importantly, guide towards more judicious use of surgical management, with improved mortality and digestive autonomy. CT scan also accurately predicts risk of stricture formation. We propose an algorithm for the use of CT scan, rather than endoscopy, as the first‐line investigation in the assessment of caustic ingestion.
- 18 March 2019
- Published by Wiley in Emergency Medicine Australasia
- Vol. 31 (3) , 479-482
Caustic ingestion: Has the role of the gastroenterologist burnt out?
Caustic ingestion is a frequent presentation to EDs and encompasses a wide range of injury to the gastrointestinal tract. Endoscopy has long been considered the gold standard of investigation, even in patients with low likelihood of severe injury, and informs the decision for emergency surgery. However, recent evidence suggests that computed tomography (CT) scan can accurately diagnose digestive tract necrosis and, more importantly, guide towards more judicious use of surgical management, with improved mortality and digestive autonomy. CT scan also accurately predicts risk of stricture formation. We propose an algorithm for the use of CT scan, rather than endoscopy, as the first‐line investigation in the assessment of caustic ingestion.
- 22 October 2018
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 50 (4) , 888-893
Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme—a Propensity Score Adjusted Analysis
To assess the overall survival (OS) in those with hepatocellular carcinoma (HCC) diagnosed within a programmatic, centrally co-ordinated, regional screening programme.
- 22 October 2018
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 50 (4) , 888-893
Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme—a Propensity Score Adjusted Analysis
To assess the overall survival (OS) in those with hepatocellular carcinoma (HCC) diagnosed within a programmatic, centrally co-ordinated, regional screening programme.